Vamikibart

Summary

Vamikibart (CHEMBL5315020) is a phase-3 clinical-stage antibody; indicated across 2 conditions.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315020
Name	Vamikibart
Type	Antibody
Max phase	3

Also known as: Ebi-031, EBI031, RG-6179, RG6179, RO-7200220, RO7200220, Vamikibart, VAMIKIBART

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05642312	PHASE3	COMPLETED	A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
NCT05642325	PHASE3	COMPLETED	Vamikibart in Participants With Uveitic Macular Edema
NCT05151731	PHASE2	COMPLETED	A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
NCT05151744	PHASE2	COMPLETED	A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
NCT02842541	PHASE1	WITHDRAWN	Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
NCT06771271	PHASE1	COMPLETED	A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).